Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0001193125-26-223984

Chief Commercial Officer sold 228 shares at $18.36 ($4,186)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Friedl-Naderer Johanna Chief Commercial Officer 2026-05-13 Sale 10b5-1 −228 $18.36 $4,186 154,353 D: show line 1 in the form
Open-market sales · 228 sh · avg $18.36 · $4,186
Loading xslF345X06/ownership.xml…